Stocks to sell

I’ve been waiting to write about iBio (NYSEAMERICAN:IBIO) in order to see their earnings report and give readers a better handle on the latest IBIO news. As usual, there is nothing worth investing in with this company. Most investors should stay far away from IBIO stock. Source: Shutterstock In fact, the only thing of note

Would you pay 30 times revenue for a money-losing “growth” company that had stopped growing? But that’s where Beyond Meat (NASDAQ:BYND) finds itself after reporting a loss of $19.3 million, 31 cents per share, for the quarter ending in September. Sales for Beyond Meat stock came to $94.4 million, up just 2.7% from a year

Total return. That’s a combination of growth and the dividend a stock returns. The dividend is kind of like a guaranteed return, even if the stock doesn’t perform or the market rolls over. That’s why companies that offer dividends are considered shareholder friendly. They return some of their net profits to their investors and generally

Near the $50 per share price level, will Nio (NYSE:NIO) climb even higher? It’s possible. After a strong earnings report, investors remain confident in the China-based electric vehicle (EV) maker’s prospects. Sure, its projected growth makes it worthy of a premium valuation. Yet, it’s questionable whether today’s share price overestimates its long-term prospects. Source: Robert

This year will be remembered for its global economic contraction. And while there’s hope that next year will see some improvement,  another wave of coronavirus infections can potentially imply a double-dip recession and leave investors scrambling for stocks to sell. Chris Williamson, chief business economist at HIS Markit believes that a lockdown will translate into

With the crazy world we’re living in, it was almost inevitable that the markets had at least one more surprise in store. Sure enough, a big one came last week in the form of a very positive third-quarter earnings report for ElectraMeccanica (NASDAQ:SOLO). The niche electric-vehicle (EV) manufacturer, specializing in the three-wheeled, single-seater Solo, reported

A recent article I saw online discussed how Citron Research’s Andrew Left believes Nio (NYSE:NIO) is no longer a good investment, despite the fact he first recommended the Chinese electric vehicle manufacturer in November 2018 when it was trading around $7.  Source: Andy Feng / Shutterstock.com “While we commend Baillie Gifford (love those people) and

The shares of Inovio Pharmaceuticals (NASDAQ:INO) were on fire this spring after the company had become one of the leaders of the Covid-19 vaccine race. INO stock soared 860% in the first half of the year, comfortably beating the majority of its peers. Source: Shutterstock However, due to the lack of detail in the company’s

If you had to pick one sector that you can rely on when things get difficult, sin stocks would represent an incredibly tempting proposition. While companies based on a cynical or even outright lurid business model are often attractive in the best of times, it’s at our worst when this sector has a powerful draw.

Inovio Pharmaceuticals (NASDAQ:INO) stock has fallen more than 64% since its peak at the end of June and more than 47% since my last article on June 23. I was skeptical of the company’s prospects and value at the time and I remain so today. Source: Ascannio / Shutterstock.com At the time I wrote that

I’ll admit to knowing nothing about Ever-Glory International (NASDAQ:EVK), a China-based apparel manufacturer and retailer, before I conducted research for this column. But I knew there had to be something about EVK stock that was drawing the attention of our readers. A quick glance shows some significant price action and a surge of trading volume

In July 2020, McKinsey indicated that 250 vaccine candidates are being pursued globally. The consulting firm also estimated that between five to seven vaccines would be approved in the next two years. Inovio Pharmaceuticals (NASDAQ:INO) has been in the race for the vaccine against Covid-19 and INO stock has exhibited high volatility. Source: Ascannio /

It’s been an incredible comeback year for iBio (NYSEAMERICAN:IBIO). Up until 2020, IBIO stock had a long and unfortunate run as a publicly traded investment. Shares dropped from a peak of $55 each in 2011 to as low as 5 cents last year. However, for the fledgling biotech and vaccine company, the novel coronavirus gave it

Vehicle rental company Hertz Global (OTCMKTS:HTZGQ) and Hertz stock is no longer traded on the New York Stock Exchange. On Oct. 29, Intercontinental Exchange (NYSE:ICE), which owns the NYSE announced, “the staff of NYSE Regulation has determined to suspend trading in the common stock of Hertz Global Holdings, Inc. (the “Company”) — ticker symbol HTZ —

As the world’s second-largest economy with a middle class that’s still significantly expanding, China represents an investor’s dream market. Frankly, without the country, many companies would cease to exist because they were originally tied to now-matured sectors. But the allure of China is also its pitfall. As an investor, you must be careful to avoid

There are investors out there who see this market as being in a bubble, or something close. And I’d expect many of those investors would point to Exxon Mobil (NYSE:XOM) stock as “Exhibit A” in their argument. Source: Harry Green / Shutterstock.com After all, many growth stocks that are barely profitable — or not profitable

At a time like this, it doesn’t seem like valuations matter all that much. For instance, tech stocks are exploding to the upside, with price-to-sales ratios through the roof. Yet in some cases, they have little or no profit to show. In fact, it seems that there are overvalued stocks everywhere. Investors should be wary,

On Monday, Pfizer (NYSE:PFE) announced a breakthrough in its search for a novel coronavirus vaccine. The company’s candidate — developed in partnership with Biontech (NASDAQ:BNTX) — has now reached 90% efficacy in preventing the disease in healthy volunteers. Needless to say, this news came as a bolt out of the blue. Prior to the big announcement,

Eastman Kodak (NYSE:KODK) has had a long slow fall from grace. Since missing the evolution to digital photography, Kodak has struggled. The company filed bankruptcy 2012, and since emerging from reorganization, it has desperately swung from one half-baked business strategy to the next. For example, the less said of 2018’s Kodak cryptocurrency, the better. However,

Naked Brand Group (NASDAQ:NAKD) stock has left its shareholders feeling a stiff chill. Since 2015, adjusting for reverse splits, NAKD stock has plummeted from $2,000 per share to just 7 cents today. That’s a greater than 99.9% wipeout of value. Source: Shutterstock After this sort of plunge, you might think that there’d be value, or at